New therapeutic opportunities in improving the antenatal management of obese women

Authors

DOI:

https://doi.org/10.18370/2309-4117.2023.68.58-64

Keywords:

pregnancy, pregravid preparation, complications, obesity, prevention, myo-inositol, perinatal results

Abstract

Research objectives: to assess the effectiveness of the developed treatment complex on the course of pregnancy and childbirth in obese women.
Materials and methods. 135 pregnant women were examined depending on the degree of obesity and received treatment. The women were examined and treated in the Department of Pathology of Pregnancy and Childbirth, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine” during 2019–2021.
The developed medical complex included: Miofolic 2 sachets/day 3 months before pregnancy and throughout the gestation period; in case of insufficiency or deficiency of vitamin D, this vitamin was prescribed in a dose of 4000 IU/day; magnesium citrate 250–300 mg/day during pregnancy; micronized progesterone vaginally 200–400 mg/day in the II phase of the menstrual cycle before conception and up to 34 weeks of gestation (if necessary); individual programs of prenatal psychological rehabilitation using psychophysical exercises were used depending on the psychosomatic disorders.
Results. it was found that the number of pregnant women of older reproductive age is increasing. There was a decrease in pre-pregnancy weight (which was positively reflected in the subsequent course of pregnancy) at the 3 months before the onset of pregnancy in women with lifestyle modification (diet therapy, dosed physical activities) and who intake a developed treatment complex at the pre-gravid stage.
A peculiarity of the somatic morbidity of pregnant women was the combination of various types of extragenital diseases. Significant differences were found between chronic diseases of the cardiovascular system and diseases of the gastrointestinal tract and liver compared to the control group. The course of pregnancy largely depended on the reproductive system status before fertilization – an increase in the frequency of infertility was noted with an increase in the woman’s body mass index.
Pregnant women who received the developed treatment complex had fewer pregnancy complications, the frequency of which was not significantly different from the control group. At the same time, against the background of the treatment, their lipid profile and vitamin and mineral supply improved. All this had a positive effect on the pregnancy outcomes.
Conclusions. Developed medical complex including myo-inositol, starting from the pre-gravid period and throughout pregnancy, helps to reduce insulin resistance in obese women, improve the lipid profile and normalize the leptin level, which has a positive effect on the course of pregnancy and childbirth and improves perinatal outcomes.

Author Biographies

I.A. Zhabchenko, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Kyiv

MD, professor, сhief of the Department of pathology of pregnancy and childbirth

O.R. Siudmak, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Kyiv

Junior researcher, Department of Pathology of Pregnancy and Childbirth

I.S. Lishchenko, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Kyiv

MD, researcher, Department of Pathology of Pregnancy and Childbirth

T.M. Kovalenko, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Kyiv

PhD in physical education and sport, senior researcher, Department of Pathology of Pregnancy and Childbirth

O.M. Bondarenko, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Kyiv

PhD, senior researcher, Department of Pathology of Pregnancy and Childbirth

References

  1. Jensen, M.D., Ryan, D.H., Apovian, C.M., et al. “2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.“ J Am Coll Cardiol 63.25 (2014): 3029–30. DOI: 10.1016/j.jacc.2013.11.004
  2. Bulavenko, O.V., Dzys, N.P., Furman, O.V. “Treatment of endometrial hyperplastic processes in women of late reproductive age with excess weight.“ Reproductive Health. Eastern Europe 39.3 (2015): 121–7.
  3. Jahre, A., Dietl, S., Cupisti, M., et al. “Pregnancy and Obstetrical Outcomes in Women Over 40 Years of Age Schwangerschaft und Geburt bei Frauen über 40.“ Zollner Geburtshilfe Frauenheilkd 75.8 (2015): 827–32.
  4. Zhabchenko, I.A., Siudmak, O.R. “Problems of delayed childbirth: peculiarities of fertility in women of older reproductive age and methods of their correction.“ Reproductive endocrinology 49.5 (2019): 47–53. DOI: 10.18370/2309-4117.2018.49.43-49
  5. Persson, M., Johansson, S., Cnattingius, S. “Inter-pregnancy Weight Change and Risks of Severe Birth-Asphyxia-Related Outcomes in Singleton Infants Born at Term: A Nationwide Swedish Cohort Study.“ PLoS Med 13.6 (2016): E1002033. DOI: 10.1371/journal.pmed.1002033
  6. Chekman, I.S., Gorchakova, N.O., Berezhny, V.V., et al. “Pharmacology of vitamin D.“ Modern questions of pediatrics 82.2 (2017): 28–36. DOI 10.15574/SP.2017.82.28
  7. Komisarenko, Y.I., Bobryk, M.I., Sidorova, I.V., Burka, О.А. “Vitamin D: the potential of clinical solutions in the doctor’s practice.“ Reproductive endocrinology 20.6 (2014): 105–8.
  8. Povorozniuk, V.V., Pludovsky, P. Deficiency and insufficiency of vitamin D: epidemiology, diagnosis, prevention and treatment. Kyiv. Publisher O. Zaslavskyy (2015): 262 p.
  9. Shummers, L., Hutcheon, J.A., Bodnar, L.M., et al. “Risk of adverse pregnancy outcomes by prepregnancy body mass index: a population-based study to inform prepregnancy weight loss counseling.“ Obstet Gynecol 125.1 (2015): 133–43. DOI: 10.1097/AOG.0000000000000591
  10. De Souza, L.R., Berger, H., Retnakaran, R., et al. “First-Trimester Maternal Abdominal Adiposity Predicts Dysglycemia and Gestational Diabetes Mellitus in Midpregnancy.“ Diabetes Care 39.1 (2016): 61–4. DOI: 10.2337/dc15-2027
  11. Doherty, D.A., Newnham, J.P., Bower, C., et al. “Implications of Polycystic Ovary Syndrome for Pregnancy and for the Health of Offspring.“ Obstet Gynecol 125 (2015): 1399–408.
  12. Zhabchenko, I.A., Sydmak, O.R., Lishchenko, I.S., et al. “Peculiarities of micronutrient metabolism in obese pregnant women (literature review).“ Zaporizhzhya Medical Journal 23.3.126 (2021): 446–53. DOI: 10.14739/2310-1210.2021.3.203959
  13. Tucker, M.E. Lifestyle Intervention Improves Fertility in Obese Women (2019). Available from: [https//www.medscape.com/ viewarticle/911281].
  14. Khmil, M.S., Khmil-Dosvald, A.S., Khmil S.V., Pidhaina, І.Y., et al. “Prospects for the use of inositol in women with polycystic ovary syndrome (literature review).“ Herald of social hygiene and health care organizations of Ukraine 4.78 (2018): 82–9. DOI: 10.11603/1681-2786.2018.4.10035
  15. Tatarchuk, T.F., Ganzhy, I.Y., Pedachenko, N.Y., Kapshuk, I.M. “Modern possibilities of non-hormonal treatment of polycystic ovary syndrome in obese women.“ Reproductive endocrinology 13.5 (2013): 19–21. DOI: 10.18370/2309-4117.2013.13.19-21
  16. Bevilakua, A., Carlomanjo, J., Gerley, S., et al. “Results of an international consensus conference on the use of myo-inositol and D-chiro-inositol in obstetrics and gynecology and, in particular, in IVF. “ A word about health 19 (2019). Obstetrics. Available from: [https:// ozdorovvvvie.com.ua/category/rozdili/akusherstvo-uk].
  17. Facchinetti, F., Appeteccia, M., Aragona, C., et al. “Experts’ opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond.“ Expert Opin Drug Metab Toxicol 16.3 (2020): 255–74. DOI: 10.1080/17425255.2020.1737675
  18. Unfer, V., Facchinetti, F., Orrù, B., et al. “Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.“ Endocrine Connection 6.8 (2017): 647–58. DOI: 10.1155/2016/1849162
  19. Croze, M.L., Soulage, C.O. “Potential role and therapeutic interests of myo-inositol in metabolic diseases.“ Biochimie 95.10 (2013): 1811–27. DOI: 10.1016/j.biochi.2013.05.011
  20. Kalugina, L.V., Yusko, T.I. “Myo-inositol: therapeutic possibilities and prepregnancy preparation for polycystic ovary syndrome (literature review).“ Reproductive endocrinology 42.4 (2018): 31–2.
  21. Spätling, L., Classen, H.G., Kisters, K., et al. “Supplementation of Magnesium in Pregnancy.“ J Preg Child Health 4.1 (2017): 302. DOI:10.4172/2376-127X.1000302
  22. Tovstanovskaya, V.A., Alatorskikh, A.E. “Prospects for the use of magnesium and vitamin B6 preparations in pregnant women with undifferentiated connective tissue dysplasia.“ Perinatology and pediatrics 73.1 (2018): 30–5. DOI: 10.15574/PP.2018.73.30
  23. “Does the content of magnesium affect the course of pregnancy: the opinion of experts.“ Medical aspects of women’s health 108.3 (2017): 10–3. Available from: [https://mazg.com.ua/uploads/issues/2017/3(108)/mazg173_10- 13_1868cd2480e3f41453540e52deb5c1a5.pdf].
  24. Zhabchenko, I.A. “Magnesium in obstetric practice: known facts and new possibilities.“ Medical aspects of women’s health 122–123.1–2 (2019): 32–8.
  25. Lisitsyna, O.I. “The use of magnesium preparations during pregnancy.“ Man and medicine. Kazakhstan 102.7 (2018): 28–32. DOI 10.21518/2079-701x-2018-7-50-53

Downloads

Published

2023-06-30

How to Cite

Zhabchenko, I., Siudmak, O., Lishchenko, I., Kovalenko, T., & Bondarenko, O. (2023). New therapeutic opportunities in improving the antenatal management of obese women. REPRODUCTIVE ENDOCRINOLOGY, (68), 58–64. https://doi.org/10.18370/2309-4117.2023.68.58-64

Issue

No. 68 (2023)

Section

Pregnancy and childbirth

License

Copyright (c) 2023 І.А. Жабченко, О.Р. Сюдмак, І.С. Ліщенко, Т.М. Коваленко, О.М. Бондаренко

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.